Pharma Shares Gain On Higher Demand For Medicines As Covid-19 Cases Rise
Shares of pharma companies were outperforming in an otherwise weak market session as rising demand for medicines amid rising Coronavirus infections in country led to investors buying shares of pharma companies.
The gauge of pharma shares on the National Stock Exchange rose 1.4 per cent massively outperforming the Nifty 50 index which was down 3.58 per cent.
Rising Covid-19 cases in the country is leading to higher demand for medicines which is driving up the share prices of drugmakers, analysts said.
Reports of the government imposing ban on export of anti-viral drug Remdesivir owing to shortage also led to buying interest in pharma shares.
India has banned export of the anti-viral drug Remdesivir amid a surge in COVID-19 cases in the country. In an order, the government said it has banned export of Remdesivir injection and Remdesivir active pharmaceutical ingredients (API) till the pandemic situation in the country stabilises.
Cipla was top gainer among the pharma shares. The stock rose as much as 6.45 per cent to hit an all-time high of Rs 940 on the National Stock Exchange.
Divi's Labs, Dr Reddy's Labs, Torrent Pharma, Cadila Healthcare, Ipca Labs, Laurus Labs and Alkem Labs were also trading with a positive bias.
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.
